Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Brazil ETF (EWZ) vs Sanofi SA (SNY) Price & Performance

Ishares Msci Brazil ETFTrade

Price performance (Past 24H)

Key statistics

Ishares Msci Brazil ETF vs Sanofi SA — how do they compare? Ishares Msci Brazil ETF trades at $33.92, while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while Ishares Msci Brazil ETF pays none, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.

EWZSNY
Sector
Broad Market / FactorHealth
52-Week High
$41.75$52.34
52-Week Low
$27.36$41.33
Market Cap
$104.30B
Enterprise Value
$124.19B
Dividend Yield
5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Brazil ETF

EWZ, the iShares MSCI Brazil ETF, trades at $34.04, down 3.27% on the day. The technical outlook is bearish based on moving averages, though oscillators suggest potential for a near-term bounce. Recent news highlights institutional interest, with Empowered Funds LLC and Allspring Global Investments increasing positions in Q2 2026, while analysts debate the fund's value relative to competitors like FLBR due to its higher expense ratio.

The outlook for EWZ hinges on Brazil's economic trajectory, particularly interest rate cuts and commodity prices. Opportunities exist if Brazil's growth accelerates, but risks include U.S. tariff impacts on Brazilian exports and inconsistent dividend payouts reliant on volatile commodity stocks like Petrobras and Vale.

Sanofi SA

SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.

Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ishares Msci Brazil ETF

EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.

Read more on EWZ

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY